Bildkälla: Stockfoto

Calliditas: An approval in China during 2023 is now more likely - Redeye

Calliditas partner in China (including South Korea, Hong Kong, Macau, Taiwan and Singapore) Everest Medical has announced that the Center for Drug Evaluation in China has recommended a Priority Review for Nefecon.

Calliditas partner in China (including South Korea, Hong Kong, Macau, Taiwan and Singapore) Everest Medical has announced that the Center for Drug Evaluation in China has recommended a Priority Review for Nefecon.
Börsvärldens nyhetsbrev
ANNONSER